By Jon Cohen Just because information is difficult to obtain, it doesn’t mean that the obtained information is particularly meaningful—or accurate. I plan to discuss…
Comments closedCategory: Articles
I became so overwhelmed by covering COVID-19 that I no longer had time to post individual stories. So here are links to my latest stories…
Comments closed
The United States government routinely sues pharmaceutical companies for making false claims, bilking Medicare, illegal kickbacks, and sloppy manufacturing practices. But on 6 November, the…
Comments closedNote: This is a draft of a story I wrote in 2005 for the New York Times Magazine. Despite enthusiastic support from my immediate editor,…
Comments closed
An experimental dengue vaccine has shown promising early results in a large, multicountry trial, but critical questions remain about its effectiveness and safety. Still unclear,…
Comments closed
A 66% price slash of a little used but powerful drug that prevents tuberculosis (TB) could help stave off the deadly lung disease in millions…
Comments closed
By Jon Cohen, Jocelyn Kaiser Two major U.S. biomedical research funders plan to each put at least $100 million over 4 years toward bringing cutting-edge, gene-based treatments…
Comments closed
This story was supported by the Pulitzer Center. On a lightly snowing Sunday evening, a potential participant in Denis Rebrikov’s controversial plans to create gene-edited babies meets…
Comments closed
This story was supported by the Pulitzer Center. Earlier this month, Denis Rebrikov went to an old mansion in Moscow that now houses the Russian…
Comments closed